MedTrace Logo

Medtronic RESOLUTE ONYX Core (2.25 mm - 4.0 mm) Clinical Study

NCT02419521 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 75

Last updated 2019-04-03

Study results available
· View outcomes & findings →

Summary

The purpose of this trial is to assess the safety and efficacy of the Resolute Onyx Zotarolimus-Eluting Coronary Stent System for the treatment of de novo lesions in native coronary arteries with a reference vessel diameter of 2.25 mm to 4.2 mm.

Conditions

Interventions

DEVICE

Resolute Onyx Stent - 2.25 mm - 4.0 mm

Sponsors & Collaborators

  • Medtronic Vascular

    lead INDUSTRY

Principal Investigators

  • Matthew J. Price, MD, FACC, FSCAI · Scripps Green Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-07-07
Primary Completion
2016-07-05
Completion
2018-12-03

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02419521 on ClinicalTrials.gov